Sign inJoin waitlistJoin the waitlist

Xiuning Le

Associate Professor, Thoracic/Head and Neck Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Dana-Farber Cancer Institute
2014–2017
Hematology and Medical Oncology
Beth Israel Deaconess Medical Center
2013–2016
Gastroenterology
2011–2014
Internal Medicine
UMass Chan Medical School
2010–2013
PEKING UNION MED UNIV, (PEKING UNION MEDICAL COLL), BEIJING, CHINA
1999–2003

Research

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
New England Journal of Medicine · 2020 · 717 citations
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Nature Medicine · 2021 · 558 citations
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Nature · 2021 · 421 citations

John Heymach
91 papers
Jianjun Zhang
66 papers
Don Gibbons
49 papers
Lingzhi Hong
36 papers · 21 as a fellow
Yasir Elamin
36 papers · 1 as a fellow
Natalie Vokes
31 papers
Tina Cascone
30 papers
JL
Joanna Lee
27 papers
Ara Vaporciyan
26 papers
Marcelo Negrao
25 papers
Mehmet Altan
22 papers
Lauren Byers
21 papers

Clinical trials

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2027
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2023–2028
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2022–2026
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2021–2022